- Vaccines from Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) and AstraZeneca (NASDAQ:AZN) are effective against the rapidly spreading Delta variant of COVID-19, according to a new analysis from the UK.
- The analysis from Public Health England found that for the Delta variant, vaccine effectiveness for preventing hospitalization was 96% for Pfizer/BioNTech, and 92% for AstraZeneca.
- For preventing symptomatic disease, the figures were, respectively, 88% and 67%.
- Pfizer shares are down 1.9% to $39.39, BioNTech shares are down 6.2% to $223.69, and AstraZeneca shares are down 0.4% to $58.53 in afternoon trading.